Profile of thyroid hormones in breast cancer patients
Profile of thyroid hormones in breast cancer patients
复制标题
DOI：
10.1590/s0100-879x2005000500014
复制
发表时间：
2005-05-01
影响因子：
2.3
通讯作者：
Nogueira, C.R.
中科院分区：
文献类型：
--
作者：
Saraiva, P.P.;Figueiredo, N.B.;Nogueira, C.R.
雌激素与乳腺癌的关系已被证实；然而，乳腺癌和甲状腺疾病之间的联系是有争议的。甲状腺激素对培养的乳腺癌细胞生长的雌激素样作用已有报道。本研究的目的是确定乳腺癌患者甲状腺激素的分布。分析26例年龄在30 ~ 85岁的乳腺癌患者和年龄匹配的正常对照（N = 22）的血清中游离三碘甲状腺原氨酸（T3F）、游离甲状腺素（T4F）、促甲状腺激素（TSH）、抗过氧化物酶抗体（TPO）和雌二醇（E-2）的含量。免疫组化法检测肿瘤组织中雌激素受体β (ER β)水平。甲状腺疾病发生率高于对照组（58% vs 18%, P < 0.05）。亚临床甲状腺功能亢进是患者中最常见的疾病（31%）；甲状腺功能减退（8%）和抗tpo抗体阳性（19%）。亚临床甲状腺功能减退是对照组中发现的唯一功能障碍（18%）。甲状腺功能亢进与绝经后患者有关，这组乳腺癌患者的平均T-3和T-4值明显高于对照组，TSH水平明显低于对照组。大多数ER - β阳性肿瘤聚集在绝经后患者中，该亚组中所有出现亚临床甲状腺功能亢进的病例均伴有ER - β阳性肿瘤。6例绝经前患者中仅有1例存在亚临床甲状腺功能亢进。我们发现绝经后乳腺癌患者甲状腺激素/E-2比值显著升高（P < 0.05），提示这种失衡可能引起肿瘤生长促进作用。
Estrogen involvement in breast cancer has been established; however, the association between breast cancer and thyroid diseases is controversial. Estrogen-like effects of thyroid hormone on breast cancer cell growth in culture have been reported. The objective of the present study was to determine the profile of thyroid hormones in breast cancer patients. Serum aliquots from 26 patients with breast cancer ranging in age from 30 to 85 years and age-matched normal controls (N = 22) were analyzed for free triiodothyronine (T3F), free thyroxine T4F), thyroid-stimulating hormone (TSH), antiperoxidase antibody (TPO), and estradiol (E-2). Estrogen receptor beta (ER beta) was determined in tumor tissues by immunohistochemistry. Thyroid disease incidence was higher in patients than in controls (58 vs 18%, P < 0.05). Subclinical hyperthyroidism was the most frequent disorder in patients (31%); hypothyroidism (8%) and positive anti-TPO antibodies (19%) were also found. Subclinical hypothyroidism was the only dysfunction (18%) found in controls. Hyperthyroidism was associated with postmenopausal patients, as shown by significantly higher mean T-3 and T-4 values and lower TSH levels in this group of breast cancer patients than in controls. The majority of positive ER beta tumors were clustered in the postmenopausal patients and all cases presenting subclinical hyperthyroidism in this subgroup concomitantly exhibited Er beta-positive tumors. Subclinical hyperthyroidism was present in only one of 6 premenopausal patients. We show here that postmenopausal breast cancer patients have a significantly increased thyroid hormone/E-2 ratio (P < 0.05), suggesting a possible tumor growth-promoting effect caused by this misbalance.